Clinical Trials
Our clinical development program is focused on improving the lives of cancer patients utilizing innovative approaches either in monotherapy or in combination with existing therapies.
|
|
Study |
Indication |
Combination |
Phase I |
Phase II |
Pivotal |
|
Resminostat |
Assorted studies |
Assorted cancers |
– / Chemotherapy |
|
|
|
|
|
|
|
||||
|
|
|
|
||||
|
RESMAIN |
Cutaneous T-cell Lymphoma (CTCL) |
– |
|
|
|
|
|
|
|
|
||||
|
|
|
|
||||
|
BTC* |
Biliary tract cancer |
S1 Chemotherapy |
|
|
|
|
|
|
|
|
||||
|
|
|
|
||||
|
Domatinostat |
TOPAS |
Hematologic malignancies |
– |
|
|
|
|
|
|
|
||||
|
|
|
|
||||
|
SENSITIZE |
CI refractory or non-responsive melanoma |
CI |
|
|
|
|
|
|
|
|
||||
|
|
|
|
||||
|
EMERGE** |
CI non-responsive MSS gastro-intestinal cancer |
CI |
|
|
|
|
|
|
|
|
||||
|
|
|
|
||||
|
MERKLIN 1 |
CI naïve Merkel cell carcinoma (MCC) |
CI |
|
|
|
|
|
|
|
|
||||
|
|
|
|
||||
|
MERKLIN 2 |
CI refractory/relapsed Merkel cell carcinoma (MCC) |
CI |
|
|
|
|
|
|
|
|
||||
|
|
|
|
||||
|
DONIMI** |
Melanoma, neo-adjuvant |
CI |
|
|
|
|
|
|
|
|
||||
|
|
|
|
||||
|
„Triple Combo“** |
Melanoma |
CI + CI |
|
|
|
|
|
|
|
|
||||
|
|
|
|
* Performed by 4SC’s partner Yakult Honsha; ** Investigator-sponsored trial; CI: Checkpoint inhibitor, a specific type of immunotherapy; MSS: Microsatellite stable; dark blue: completed; middle blue: ongoing; light blue: in preparation, grey: planned.